After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

WEST LAFAYETTE, Ind. — Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing ...

Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck stock has shown some solid short-term strength, with its stock price of $98.90 comfortably sitting above its eight-day and 20-day simple moving averages (SMAs) of $97.81 and $98.64 ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

That nod, which covers a restricted population ... s Rxulti (marketed as Rexulti in the U.S.) , Merck’s Sivextro and Neurim Pharmaceutical’s Slenyto. As for withdrawals, Advanz Pharma in ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.